BRPI1010764A2 - "sais de derivados de pirazolon-azo biciclo substituído, método de preparação e uso do mesmo" - Google Patents

"sais de derivados de pirazolon-azo biciclo substituído, método de preparação e uso do mesmo"

Info

Publication number
BRPI1010764A2
BRPI1010764A2 BRPI1010764A BRPI1010764A BRPI1010764A2 BR PI1010764 A2 BRPI1010764 A2 BR PI1010764A2 BR PI1010764 A BRPI1010764 A BR PI1010764A BR PI1010764 A BRPI1010764 A BR PI1010764A BR PI1010764 A2 BRPI1010764 A2 BR PI1010764A2
Authority
BR
Brazil
Prior art keywords
pyrazolazo
azo
salts
substituted
preparation
Prior art date
Application number
BRPI1010764A
Other languages
English (en)
Inventor
Hejun Lü
Hongbo Fei
Peng Cho Tang
Yiqian Chen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai Hengrui Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai Hengrui Pharm Co Ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of BRPI1010764A2 publication Critical patent/BRPI1010764A2/pt
Publication of BRPI1010764B1 publication Critical patent/BRPI1010764B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/05—Mono-, di- or tri-ethylamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1010764A 2009-06-11 2010-05-28 sais farmaceuticamente aceitáveis de derivados de pirazolon-azo biciclo substituído, seu uso e seu processo de preparação, composição farmacêutica e seu processo de preparação BRPI1010764B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009100529461A CN101921232A (zh) 2009-06-11 2009-06-11 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
PCT/CN2010/000760 WO2010142137A1 (zh) 2009-06-11 2010-05-28 双环取代吡唑酮偶氮类衍生物的盐，及其制备方法和应用

Publications (2)

Publication Number Publication Date
BRPI1010764A2 true BRPI1010764A2 (pt) 2016-03-22
BRPI1010764B1 BRPI1010764B1 (pt) 2020-04-07

Family

ID=43308392

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010764A BRPI1010764B1 (pt) 2009-06-11 2010-05-28 sais farmaceuticamente aceitáveis de derivados de pirazolon-azo biciclo substituído, seu uso e seu processo de preparação, composição farmacêutica e seu processo de preparação

Country Status (17)

Country Link
US (2) US8642637B2 (pt)
EP (1) EP2441457B1 (pt)
JP (1) JP5821079B2 (pt)
KR (1) KR101738181B1 (pt)
CN (2) CN101921232A (pt)
AU (1) AU2010258027B2 (pt)
BR (1) BRPI1010764B1 (pt)
CA (1) CA2762916C (pt)
DK (1) DK2441457T3 (pt)
ES (1) ES2452039T3 (pt)
MX (1) MX2011012639A (pt)
PL (1) PL2441457T3 (pt)
PT (1) PT2441457E (pt)
RU (1) RU2538977C2 (pt)
UA (1) UA107353C2 (pt)
WO (1) WO2010142137A1 (pt)
ZA (1) ZA201108249B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
CN103360317B (zh) * 2012-04-11 2016-12-14 齐鲁制药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及用途
CN103910718B (zh) * 2013-01-08 2018-08-14 齐鲁制药有限公司 双环取代的吡唑酮偶氮类化合物、其制备方法和用途
CN106146330B (zh) * 2015-04-21 2018-04-06 江苏威凯尔医药科技有限公司 一种制备艾曲波帕中间体的方法
WO2017042839A1 (en) * 2015-09-08 2017-03-16 Actavis Group Ptc Ehf. Novel eltrombopag salt and preparation thereof
RU2733844C2 (ru) * 2016-01-22 2020-10-07 Цзянсу Хэнжуй Медицин Ко., Лтд. Фармацевтическая композиция, включающая бициклозамещенное азопроизводное пиразолона или его соль, и способ их получения
CN107870217B (zh) * 2016-09-26 2022-03-04 齐鲁制药有限公司 艾曲波帕中间体ⅰ有关物质的检测方法
WO2018133818A1 (zh) * 2017-01-19 2018-07-26 江苏恒瑞医药股份有限公司 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体
CN110028497B (zh) * 2018-01-11 2020-11-17 江苏恒瑞医药股份有限公司 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法
EP3909645A4 (en) * 2019-01-08 2022-07-27 Jiangsu Hengrui Medicine Co., Ltd. DOSING REGIME FOR A BICYCLIC SUBSTITUTE PYRAZOLONEAZOLE DERIVATIVE
TW202302090A (zh) * 2021-04-30 2023-01-16 大陸商江蘇恒瑞醫藥股份有限公司 血小板生成素受體激動劑的給藥方案
US20250144077A1 (en) * 2022-01-25 2025-05-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Dosage regimen for thrombopoietin receptor agonist

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002529502A (ja) 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CN1376150A (zh) 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
AU770564B2 (en) 1999-09-10 2004-02-26 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1228051A1 (en) 1999-11-05 2002-08-07 SmithKline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
ES2275567T3 (es) 1999-12-06 2007-06-16 Smithkline Beecham Corporation Mimeticos de4 trombopoietina.
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
WO2003103686A1 (en) * 2002-06-06 2003-12-18 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2007518719A (ja) 2003-12-26 2007-07-12 アラーガン　インコーポレイテッド ＲＡＲγレチノイド受容体アンタゴニスト活性を有する二置換カルコンオキシム
CA2630234A1 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
CA2670345A1 (en) * 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
CN101481352A (zh) * 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
HK1154503A1 (en) 2012-04-27
EP2441457A1 (en) 2012-04-18
BRPI1010764B1 (pt) 2020-04-07
US20140140953A1 (en) 2014-05-22
CN101921232A (zh) 2010-12-22
WO2010142137A1 (zh) 2010-12-16
US9120762B2 (en) 2015-09-01
KR20120028334A (ko) 2012-03-22
PT2441457E (pt) 2014-03-20
EP2441457A4 (en) 2012-10-31
UA107353C2 (en) 2014-12-25
AU2010258027A1 (en) 2011-12-22
CN102159217B (zh) 2012-10-03
CA2762916A1 (en) 2010-12-16
ZA201108249B (en) 2012-07-25
CN102159217A (zh) 2011-08-17
KR101738181B1 (ko) 2017-05-19
ES2452039T3 (es) 2014-03-31
RU2011153934A (ru) 2013-07-20
EP2441457B1 (en) 2014-01-01
JP5821079B2 (ja) 2015-11-24
AU2010258027B2 (en) 2015-01-29
CA2762916C (en) 2018-06-12
PL2441457T3 (pl) 2014-06-30
JP2012529442A (ja) 2012-11-22
RU2538977C2 (ru) 2015-01-10
US8642637B2 (en) 2014-02-04
DK2441457T3 (en) 2014-03-10
MX2011012639A (es) 2011-12-14
US20120164102A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
BRPI1010764A2 (pt) "sais de derivados de pirazolon-azo biciclo substituído, método de preparação e uso do mesmo"
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
BR112014014547A2 (pt) compostos antagonistas de e-selectina, composições e métodos de uso
SMT201500213B (it) Alcune triazolopirazine, loro composizioni e metodi d'uso
PT2585437E (pt) Compostos de tioacetato, composições e métodos de uso
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
BRPI0918492A2 (pt) uso de naproxen, ou sal farmaceuticamente aceitável do mesmo, e esomeprazol, ou sal farmaceuticamente aceitável do mesmo
BRPI0911688A2 (pt) "compostos de pirimidina, composições e métodos de uso"
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0909954A2 (pt) "diazacarbazóis e métodos de uso"
BR112013006016A2 (pt) compostos de azabenzotiazol, composições e métodos de uso
BRPI0916769A2 (pt) derivados de benzilbenzeno deuterados e métodos de uso
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BRPI1011876A2 (pt) "composição farmacêutica estável e métodos de uso da mesma"
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
SMT201700064B (it) Antagonisti di d2, metodi di sintesi e metodi di uso
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0812321A2 (pt) Sais de ácido etilenodiamina dissuccínico, composição contendo os ditos sais, uso e método de preparação destes.
UY33079A (es) Derivados de difenil -pirazolopiridinas, su preparación y su aplicación en terapeutica
DK2146991T3 (da) Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
BRPI1013988A2 (pt) composto, composição farmacêutica , e, uso de um composto ou um sal farmacologicamente aceitável do mesmo
BRPI1006996A2 (pt) composição, método e uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law
B06F Objections, documents and/or translations needed after an examination request according art. 34 industrial property law
B07E Notice of approval relating to section 229 industrial property law
B06T Formal requirements before examination
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law
B09A Decision: intention to grant
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/05/2010, OBSERVADAS AS CONDICOES LEGAIS.